6 | Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA
01/2020
-
08/2010 |
6 | PotassiumIBA
01/2020
-
06/2007 |
6 | Ion Channels (Ion Channel)IBA
08/2018
-
01/2003 |
4 | Sodium Channels (Sodium Channel)IBA
01/2020
-
01/2010 |
4 | dofetilide (Tikosyn)FDA Link
01/2020
-
07/2008 |
4 | (R)- N- (benzimidazol- 2- yl)- 1,2,3,4- tetrahydro- 1- naphthylamineIBA
01/2020
-
08/2010 |
3 | Potassium Channels (Potassium Channel)IBA
11/2020
-
01/2006 |
3 | AP14145IBA
01/2020
-
10/2019 |
3 | CalciumIBA
01/2020
-
04/2015 |
3 | Pharmaceutical PreparationsIBA
04/2016
-
01/2011 |
2 | vernakalantIBA
01/2020
-
10/2017 |
2 | Voltage-Gated Sodium ChannelsIBA
01/2018
-
01/2009 |
2 | Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
03/2015
-
01/2014 |
2 | SodiumIBA
01/2015
-
01/2011 |
2 | 1,3- bis(2- hydroxy- 5- trifluoromethylphenyl)ureaIBA
02/2011
-
07/2008 |
2 | 1- (3,5- bis(trifluoromethyl)phenyl)- 3- (4- bromo- 2- (1H- tetrazol- 5- yl)phenyl)thioureaIBA
03/2010
-
03/2009 |
1 | Anti-Arrhythmia AgentsIBA
01/2020 |
1 | Small-Conductance Calcium-Activated Potassium Channels (SK Potassium Channels)IBA
10/2019 |
1 | Peptides (Polypeptides)IBA
01/2018 |
1 | VenomsIBA
01/2018 |
1 | VortioxetineIBA
01/2018 |
1 | Vasodilator Agents (Vasodilators)IBA
01/2017 |
1 | Amiodarone (Amiodarona)FDA LinkGeneric
11/2016 |
1 | Neurotransmitter Agents (Neurotransmitter)IBA
03/2015 |
1 | Glutamine (L-Glutamine)FDA Link
01/2014 |
1 | Flecainide (Tambocor)FDA LinkGeneric
01/2014 |
1 | Leucine (L-Leucine)FDA Link
01/2014 |
1 | 3- (3- (pyridine- 3- yl)- 1,2,4- oxadiazol- 5- yl)benzonitrileIBA
11/2013 |
1 | Cholinergic Agents (Cholinergics)IBA
11/2013 |
1 | Cytidine Diphosphate (CDP)IBA
06/2013 |
1 | 2- (3,5- difluorophenyl)- N- (6- ((4- fluorophenyl)methylamino)- 2- morpholino- 3- pyridyl)acetamideIBA
06/2013 |
1 | Adenosine Monophosphate (AMP)IBA
06/2013 |
1 | Dizocilpine Maleate (Dizocilpine)IBA
06/2013 |
1 | Dextroamphetamine (Dexedrine)FDA LinkGeneric
06/2013 |
1 | maleic acid (maleate)IBA
06/2013 |
1 | Chlordiazepoxide (Elenium)FDA LinkGeneric
06/2013 |
1 | Type 1 Angiotensin ReceptorIBA
05/2013 |
1 | TesofensineIBA
05/2013 |
1 | Adrenergic Receptors (Adrenergic Receptor)IBA
05/2013 |
1 | Telmisartan (Micardis)FDA Link
05/2013 |
1 | Adrenergic Agents (Adrenergic Drugs)IBA
02/2012 |
1 | ArrestinIBA
01/2012 |
1 | Biomarkers (Surrogate Marker)IBA
09/2011 |
1 | Bile Acids and Salts (Bile Acids)IBA
03/2011 |
1 | Calcium Channels (Calcium Channel)IBA
01/2011 |
1 | Proteins (Proteins, Gene)FDA Link
01/2011 |
1 | Sodium-Hydrogen ExchangersIBA
01/2011 |
1 | N- (pyridin- 2- yl)- 4- (pyridin- 2- yl)thiazol- 2- amineIBA
08/2010 |
1 | NS13558IBA
03/2010 |
1 | 1- (3,5- bis- trifluoromethylphenyl)- 3- (2,4- dibromo- 6- (1H- tetrazol- 5- yl)phenyl)ureaIBA
03/2009 |
1 | Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA
03/2009 |
1 | Oxycodone (Oxycontin)FDA LinkGeneric
02/2009 |
1 | Opioid Analgesics (Opioids)IBA
02/2009 |
1 | Methadone (Dolophine)FDA LinkGeneric
02/2009 |
1 | Tramadol (K315)FDA LinkGeneric
02/2009 |
1 | Morphine (MS Contin)FDA LinkGeneric
02/2009 |
1 | Methoxamine (Methoxamine Hydrochloride)FDA Link
07/2008 |